25 days ago
CDTX
AnalystsSeamus FernandezSeamus Fernandez's Stock Forecasts
AnalystsSeamus Fernandez
Analyst Ranking
Top 13%
#601 out of 4944 analysts
Average Return
+19.59%
Win Rate
51%29 out of 57
Risk vs Reward
Poor
Good
Seamus Fernandez's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +315.93% | $13.50 | $56.15 | 2024-11-08 - 2025-07-17 | Strong Buy |
Cidara Therapeutics IncCDTX | +201.40% | $18.63 | $56.15 | 2025-05-09 - 2025-07-17 | Strong Buy |
Albireo Pharma IncALBO | +142.18% | $18.23 | $44.15 | 2022-09-08 - 2023-03-02 | Strong Buy |
Cymabay Therapeutics IncCBAY | +141.13% | $13.47 | $32.48 | 2023-08-11 - 2024-03-21 | Strong Buy |
Cidara Therapeutics IncCDTX | +120.20% | $25.50 | $56.15 | 2025-05-16 - 2025-07-17 | Strong Buy |
Seamus Fernandez Analyst Color
Get additional color on Seamus Fernandez's coverage of popular stocks
2 months ago
CDTX
2 months ago
CDTX
3 months ago
LLY
8 months ago
APGE
a year ago
LLY
a year ago
APGE
2 years ago
APGE
2 years ago
MRK
2 years ago
LLY
4 years ago
MRK
Seamus Fernandez's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 9 | Strong Buy | $942.00 | +23.70% | Maintains | 8 days ago |
Apogee Therapeutics IncAPGE | 6 | Strong Buy | $116.00 | +197.44% | Reiterates | 17 days ago |
Cidara Therapeutics IncCDTX | 4 | Strong Buy | $68.00 | +21.10% | Maintains | 25 days ago |
Amylyx Pharmaceuticals IncAMLX | 1 | Strong Buy | $17.00 | +105.31% | Initiates Coverage On | 25 days ago |
Mbx Biosciences IncMBX | 2 | Strong Buy | $44.00 | +260.80% | Reiterates | 3 months ago |
Vaxcyte IncPCVX | 4 | Strong Buy | $160.00 | +328.15% | Reiterates | 4 months ago |
Metsera IncMTSR | 1 | Strong Buy | $56.00 | +26.41% | Initiates Coverage On | 5 months ago |
Merck & Co IncMRK | 9 | Strong Buy | $122.00 | +49.66% | Maintains | 6 months ago |
Rhythm Pharmaceuticals IncRYTM | 1 | Strong Buy | $70.00 | -22.81% | Initiates Coverage On | 9 months ago |
Tenax Therapeutics IncTENX | 1 | Strong Buy | $16.00 | +172.11% | Initiates Coverage On | 9 months ago |
Icosavax IncICVX | 1 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 2 years ago |
Hillevax IncHLVX | 2 | Strong Buy | $34.00 | N/A | Maintains | 2 years ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $55.00 | N/A | Maintains | 2 years ago |
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Arcturus Therapeutics Holdings IncARCT | 1 | Strong Buy | $36.00 | N/A | Reiterates | 2 years ago |
Mineralys Therapeutics IncMLYS | 1 | Strong Buy | $32.00 | N/A | Initiates Coverage On | 2 years ago |
Structure Therapeutics IncGPCR | 1 | Strong Buy | $50.00 | N/A | Initiates Coverage On | 2 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $65.00 | N/A | Initiates Coverage On | 3 years ago |
Bristol Myers Squibb CoBMY | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Altimmune IncALT | 2 | Strong Buy | $26.00 | N/A | Maintains | 3 years ago |
Albireo Pharma IncALBO | 1 | Strong Buy | $55.00 | N/A | Initiates Coverage On | 3 years ago |
Invivyd IncIVVD | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Novartis AgNVS | 3 | Hold | N/A | N/A | Downgrades | 5 years ago |
Dermira IncDERM2 | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Tesaro IncTSRO | 4 | Hold | $75.00 | N/A | Downgrades | 7 years ago |
Intra Cellular Therapies IncITCI | 3 | Buy | $27.00 | N/A | Initiates Coverage On | 7 years ago |
Allergan PLCAGN | 3 | Buy | $220.00 | N/A | Initiates Coverage On | 7 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $54.00 | N/A | Maintains | 7 years ago |
Celldex Therapeutics IncCLDX | 2 | Hold | $45.00 | N/A | Maintains | 7 years ago |
Astrazeneca PLCAZN | 2 | Hold | $38.00 | N/A | Maintains | 7 years ago |
Pfizer IncPFE | 1 | Hold | $38.00 | N/A | Maintains | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.